Clinical Trials Browser

NCT02180867 2026-03-18

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Granuloma, Plasma Cell, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Chondrosarcoma, Mesenchymal, Dermatofibrosarcoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Nerve Sheath Neoplasms, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Perivascular Epithelioid Cell Neoplasms

Clinical Trials

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

AMPHISARC

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

INVINCIBLE-3

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

PazoDoble

Pazopanib Maintenance Phase II

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

RAR-Immune

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Pazopanib and ARQ 197 for Advanced Solid Tumors

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

EVA

Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung

NOPASS

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

TAPPAS

Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

HYPAZ

LMS03

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

Pazopanib for Metastatic Alveolar Soft Part Sarcoma

SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

EPAZ

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

PAGIST

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

Pazopanib in Treating Patients With Recurrent Glioblastoma

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma

DFSP-PAZO

Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

PAZOGIST

Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma

PASART-1